A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
• The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
• The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
xiaojuan lai
lai_xiaojuan@vcarepharmatech.com
15358160458
Time Frame
Start Date: 2025-12-26
Estimated Completion Date: 2027-08-30
Participants
Target number of participants: 420
Treatments
Experimental: VC005 Tablets Low Dose groups
Experimental: VC005 Tablets High Dose groups
Placebo_comparator: VC005 Tablets Placebo groups
Related Therapeutic Areas
Sponsors
Leads: Jiangsu vcare pharmaceutical technology co., LTD